Wedbush Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $17
Express News | Wedbush Reiterates Outperform on Stoke Therapeutics, Maintains $17 Price Target
Stoke Therapeutics (STOK) Receives a Buy From Wedbush
Stoke Therapeutics(STOK.US) Officer Sells US$137.46K in Common Stock
Stoke Therapeutics(STOK.US) Officer Sells US$32,778.87 in Common Stock
A Closer Look at 5 Analyst Recommendations For Stoke Therapeutics
Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $22
Express News | Needham Reiterates Buy on Stoke Therapeutics, Maintains $22 Price Target
Stoke Therapeutics Analyst Ratings
Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday
Express News | Stoke Therapeutics Announces Chief Operating Officer Huw Nash To Step Down, Will Continue As Chief Business Officer Effective June 18, 2024
Express News | Stoke Therapeutics Inc Files for Shelf of up to 10.8 Mln Shares of Common Stock by Selling Stockholders - SEC Filing
Companies Like Stoke Therapeutics (NASDAQ:STOK) Are In A Position To Invest In Growth
Stoke Therapeutics(STOK.US) Officer Sells US$152.19K in Common Stock
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
Insider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares
Stoke Therapeutics(STOK.US) Officer Sells US$769.5K in Common Stock
Stoke Therapeutics(STOK.US) Officer Sells US$653.53K in Common Stock
Stoke Therapeutics(STOK.US) Officer Sells US$129.33K in Common Stock
Stoke Therapeutics Insider Sold Shares Worth $653,529, According to a Recent SEC Filing